Baseman JG, Koutsky LA, The epidemiology of human papillomavirus infections. J Clin Virol 2005; 32S: S16-S24
Bosch FX, de Sanjose S. Chapter 1: Human papillomavirus and cervical cancer – burden and assessment of causality. J Natl Cancer Inst Monogr 2003; 31: 3-13.
Bosch FX, Lorincz A, Munoz N, et al. The causal relation between human papillomavirus and cervical cancer. J Clin Pathol 2002; 55: 244-265.
Brown DR et al. J Infect Dis 2005; 191: 182-92
Burd E. Human papillomavirus and cervical cancer. Clin Microbiol Rev 2003;16:1-17.
Conway K. Attitudes to Papanicolaou smears. J Psychosom Obstet Gynecol 1996; 17: 189-194.
Cuschieri KS, Cubie HA, Whitley MW et al. Multiple high risk HPV infections are common in cervical neoplasia and young women in a cervical screening population. J Clin Pathol 2004; 57: 68-72.
De Villiers EM et al.Virology 2004; 324: 17-27
Ferlay J, Bray P, Pizani P, Parkin DM. GLOBOCAN 2002: Cancer incidence, mortality and prevalence worldwide. IARC CancerBase No. 5, version 2.0. IARCPress, Lyon, 2004. Available at: http://www-dep.iarc.fr.
Franco EL, Harper DM. Vaccination against human papillomavirus infection: a new paradigm in cervical cancer control. Vaccine 2005; 23: 2388-2394.
Kitchener HC et al. Vaccine 24S3 (2006): S3/63 – S3/70
Koutsky L. Epidemiology of genital human papillomavirus infection. Am J Med 1997; 102 (5A): 3-8.
Manhart LE et al. Sex Trans Dis 2002; 29(11): 725-35
McCaffery et al. BJOG (2004); 111: 1437-1443
McIntosh N, Human papillomavirus and cervical cancer. JHPIEGO Strategy Paper No. 8, May 2000. Available at http://www.reproline.jhu.edu/english/3cc/3refman/cxca_hpv1.htm accessed 12 September 2006
Munoz N, Bosch FX, Castellsague X, et al. Against which human papillomavirus types shall we vaccinate and screen? The international perspective. Int J Cancer 2004; 111: 278-285.
Munoz N, Bosch FX, de Sanjose S et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Eng J Med 2003; 348: 518-27
Peto J, Gilham C, Deacon J, et al. Cervical HPV infection and neoplasia in a large population-based prospective study: the Manchester cohort. Br J Cancer 2004; 91: 942-953.
Schiffman M, Kjaer SK. Chapter 2: Natural history of anogenital human papillomavirus infection and neoplasia. J Natl Cancer Inst Monogr 2003; 31: 14-19.
Stanley M. Immune responses to human papillomavirus. Vaccine 2006; 24 (Suppl1) S16-22
Walboomers JMM, Jacobs MV, Manos MM, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999; 189: 12-19.
Double Helix Quantitative Market Research conducted on behalf of GSK, Aug 2005
A link to educational materials which were developed by the 2002-2004 ASCCP Section on the Cervix, for use by physicians and healthcare providers: http://www.asccp.org/edu/practice/cervix.shtml#intro
www.ecca.info/webECCA/en/glossaire.jsp